Gorlin Syndrome: Overview and Management

Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome (NBCCS), is a rare genetic disorder that predisposes individuals to multiple basal cell carcinomas and other developmental abnormalities. This article explores the causes, symptoms, diagnosis, and management of the condition, with a focus on preventing and treating the associated skin cancers.

First described by Dr. Robert Gorlin in 1960, the syndrome is characterized by a triad of features: multiple basal cell carcinomas, odontogenic keratocysts of the jaw, and skeletal anomalies. The skin cancers in this condition typically appear at a younger age than sporadic basal cell carcinomas and can be numerous, requiring vigilant surveillance and proactive treatment.

Causes and Genetics

Gorlin syndrome is caused by mutations in the PTCH1 gene, which is part of the Sonic Hedgehog signaling pathway. This gene normally acts as a tumor suppressor; when mutated, it leads to uncontrolled cell growth and the development of multiple BCCs. The condition is inherited in an autosomal dominant pattern, meaning a child has a 50% chance of inheriting the mutation from an affected parent. However, about 20-30% of cases result from new mutations with no family history.

Clinical Features and Diagnosis

The most prominent feature of this condition is the early onset of multiple BCCs, often by the second decade of life. These cancers can appear on sun-exposed and sun-protected skin, with a predilection for the face, neck, and trunk. Other diagnostic criteria include:

• Odontogenic keratocysts of the jaw (present in 75% of patients)
• Palmar and plantar pits (small depressions on hands and feet)
• Calcification of the falx cerebri (seen on skull X-ray)
• Skeletal abnormalities: bifid ribs, kyphoscoliosis, polydactyly
• Increased risk of medulloblastoma and ovarian fibromas

Diagnosis is based on clinical criteria combined with genetic testing. A diagnosis of NBCCS requires two major criteria or one major and two minor criteria. Major criteria include multiple BCCs (or one BCC before age 20), odontogenic keratocysts, palmar/plantar pits, and calcified falx.

Management and Treatment

Management of Gorlin syndrome involves a multidisciplinary approach. Regular skin examinations every 3-6 months are crucial for early detection. Treatment options include surgical excision, Mohs micrographic surgery, cryotherapy, laser therapy, and topical agents like imiquimod or 5-fluorouracil. Photodynamic therapy may also be effective. For patients with numerous lesions, oral Hedgehog inhibitors such as vismodegib or sonidegib can reduce tumor burden.

Sun protection is paramount: broad-spectrum sunscreen, protective clothing, and avoidance of tanning beds. Genetic counseling is recommended for all patients and their families. Regular dental evaluations for jaw cysts and baseline imaging for skeletal anomalies are part of standard care.

The prognosis for individuals with this syndrome is generally good with close monitoring. Although BCCs rarely metastasize, they can cause significant local destruction. Early intervention and lifestyle modifications can greatly improve quality of life.

In summary, Gorlin syndrome (nevoid basal cell carcinoma syndrome) is a lifelong condition requiring comprehensive care. Advances in genetics and targeted therapies have improved outcomes for patients with this condition. With proper management, individuals can lead active lives while minimizing the impact of this disorder.